北京海润天睿律师事务所 关于杭州百诚医药科技股份有限公司 2025 年第二次临时股东大会的法律意见书 致：杭州百诚医药科技股份有限公司 北京海润天睿律师事务所（以下简称"本所"）接受杭州百诚医药科技股份 有限公司（以下简称"公司"）委托，根据《中华人民共和国证券法》、《中华人 民共和国公司法》、《上市公司股东会规则》（以下简称"《股东会规则》"）等中华 人民共和国境内（以下简称中国境内，为本法律意见书之目的，不包括中国香港 特别行政区、中国澳门特别行政区和中国台湾地区）现行有效的法律、行政法规、 规章、规范性文件和现行有效的《杭州百诚医药科技股份有限公司章程》（以下 简称"《公司章程》"）有关规定，指派律师出席了公司于 2025 年 8 月 20 日召开 的公司 2025 年第二次临时股东大会（以下简称"本次股东大会"），并就本次股 东大会相关事项出具本法律意见书。 1、经公司 2024 年第一次临时股东大会审议通过的《公司章程》； 2、公司 2025 年 8 月 5 日刊登于巨潮资讯网等指定信息披露媒体的《杭州百 诚医药科技股份有限公司第四届董事会第三次会议决议公告》； 3、公司 2025 年 8 月 5 ...

证券代码：301096 证券简称：百诚医药 公告编号：2025-038 杭州百诚医药科技股份有限公司 2025 年第二次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示 一、会议召开和出席情况 1、 召开时间： （1）现场会议召开时间：2025 年 8 月 20 日（星期三）14:30 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时 间为：2025 年 8 月 20 日的交易时间，即 9:15-9:25，9:30-11:30 和 13:00-15:00； 通过深圳证券交易所互联网投票系统（http://wltp.cninfo.com.cn）投票的具体时 间为 2025 年 8 月 20 日 9:15-15:00 期间的任意时间。 2、 召开地点：浙江省杭州市临平区临平街道绿洲路 159 号 3、 召开方式：现场投票与网络投票相结合的方式 4、 召集人：董事会 5、 主持人：董事长、总经理楼金芳女士 参加本次股东大会现场会议和网络投票表决的中小股东及股东代理人共 89 人，代表有表决权的公司股份数合计为 39,4 ...

Market Overview - On August 20, the medical services sector rose by 0.33% compared to the previous trading day, with Haocen Medical leading the gains [1] - The Shanghai Composite Index closed at 3766.21, up 1.04%, while the Shenzhen Component Index closed at 11926.74, up 0.89% [1] Top Gainers in Medical Services - Haocen Medical (002622) closed at 3.96, up 10.00% with a trading volume of 827,000 shares and a transaction value of 322 million yuan [1] - Meinian Health (002044) closed at 5.87, up 4.45% with a trading volume of 2,284,200 shares and a transaction value of 1.323 billion yuan [1] - Baicheng Pharmaceutical (301096) closed at 56.47, up 3.31% with a trading volume of 72,900 shares and a transaction value of 401 million yuan [1] Top Losers in Medical Services - Innovation Medical (002173) closed at 23.05, down 7.21% with a trading volume of 1,255,900 shares and a transaction value of 2.968 billion yuan [2] - Boji Pharmaceutical (300404) closed at 12.36, down 6.01% with a trading volume of 819,000 shares and a transaction value of 1.015 billion yuan [2] - Nanmo Biological (688265) closed at 61.50, down 5.38% with a trading volume of 32,800 shares and a transaction value of 201 million yuan [2] Capital Flow Analysis - The medical services sector experienced a net outflow of 2.075 billion yuan from institutional investors, while retail investors saw a net inflow of 1.893 billion yuan [2][3] - The top net inflow from retail investors was in Meinian Health (002044) with 201 million yuan, despite a net outflow from institutional investors [3] - Haocen Medical (002622) had a net inflow of 114 million yuan from institutional investors, but also faced significant outflows from retail investors [3]

百诚医药公开发行股票2704.17万股，保荐机构（主承销商）为国金证券股份有限公司，保荐代表 人为余波、耿旭东。 百诚医药发行新股募集资金总额为21.53亿元，扣除发行费用后，实际募集资金净额为18.63亿 元。百诚医药最终募集资金净额比原计划多12.13亿元。百诚医药于2021年12月15日披露的招股说明书 显示，公司拟募集资金6.51亿元，全部用于杭州百诚医药科技股份有限公司总部及研发中心项目。 百诚医药发行费用总额为2.89亿元，其中国金证券股份有限公司获得承销保荐费用2.62亿元。 （责任编辑：徐自立） 中国经济网北京8月19日讯 百诚医药(301096.SZ)今日收报54.66元，跌幅4.31%。该股目前处于破 发状态。 百诚医药于2021年12月20日在深交所创业板上市，发行价格为79.60元/股。上市首日，百诚医药 创下股价高点120元，此后一路震荡下跌。 ...

Group 1 - The A-share market has seen a decline in several biopharmaceutical stocks, with notable drops including Nanmo Bio down 9%, Shanghai Yizhong down over 7%, and Nuocheng Jianhua down over 5% [1] - Other companies experiencing declines include Yangguang Nuohuo and Guangshengtang down over 4%, and Haichuang Pharmaceutical, Baicheng Pharmaceutical, Yaokang Bio, and Qianyan Bio down over 3% [1] Group 2 - Specific stock performance includes: - Nanmo Bio (688265) down 9.06% with a market cap of 5.027 billion and a year-to-date increase of 178.89% - Shanghai Yizhong (688091) down 7.23% with a market cap of 15.7 billion and a year-to-date increase of 89.98% - Nuocheng Jianhua (688428) down 5.25% with a market cap of 56 billion and a year-to-date increase of 158.55% - Yangguang Nuohuo (688621) down 4.57% with a market cap of 8.727 billion and a year-to-date increase of 107.29% - Guangshengtang (300436) down 4.26% with a market cap of 26.3 billion and a year-to-date increase of 404.68% [2]

Group 1 - A-share market sees weakness in certain biopharmaceutical stocks, with notable declines in several companies [1] - Nanmo Bio falls by 9%, while Shanghai Yizhong drops over 7% [1] - Nocare Health declines by over 5%, and Sunshine Nuohe and Guangshengtang both decrease by over 4% [1] - Haichuang Pharmaceutical, Baicheng Pharmaceutical, Yaokang Bio, and Qianyan Bio all experience declines of over 3% [1]

Core Viewpoint - The article provides a comprehensive overview of recent developments in various investment funds across China, highlighting government initiatives and private sector participation in funding technology and innovation sectors. Government-Backed Funds - Henan Province plans to establish an artificial intelligence industry fund with policies supporting R&D and providing financial incentives for outstanding enterprises [7][8] - Xiangyang has registered its first seed fund to support high-tech talent and innovation projects, with a total scale of 50 million yuan [8] - The East Jiang QFLP fund has been successfully established, marking a significant step in cross-border investment capabilities in the region [9] - Chengdu is inviting investment institutions to collaborate on a fund aimed at developing the sci-fi and future industries, targeting over 3 billion yuan [9] - The Hunan Province has initiated a 10 billion yuan fund focused on new energy vehicle components, emphasizing local investment [10] Market-Oriented Funds - The Guotiao (Taiyuan) Industrial Investment Fund has been established with a total scale of 5 billion yuan, focusing on upgrading existing projects and introducing new ones [17] - The Luoyang Dongzheng New Creation Fund has been set up with a scale of 60 million yuan, targeting high-end manufacturing and AI sectors [17] - The Yunnan Dianzhong New Area Industry Guidance Fund has been launched with a scale of 5 billion yuan, focusing on equity investments in growing companies [13] - The Fujian New Area Smart Transportation Fund aims to raise 2 billion yuan, focusing on smart transportation and related sectors [14] Corporate Participation in Funds - Greebo plans to invest 300 million yuan in the Greebo Industry Investment Fund, focusing on AI and related technologies [19] - Hengji Daxin intends to invest up to 200 million yuan in the Hangzhou Guokai Venture Capital Fund, targeting strategic emerging industries [20] - Huaren Shuanghe plans to invest up to 87 million yuan in a biopharmaceutical fund, aiming to enhance its strategic layout in synthetic biology [21] - Platinum New Materials intends to invest 80 million yuan in the Wuxi Paipu Spring Fund, focusing on advanced manufacturing and AI [22]

中国经济网北京8月18日讯百诚医药（301096）(301096.SZ)今日股价下跌，截至收盘报57.12元，跌幅 10.62%。 财通证券（601108）股份有限公司研究员华挺、赵千8月14日发布研报《百诚医药：百诚医药近况跟 踪》称，维持百诚医药"增持"评级。 ...

百诚医药发行新股募集资金总额为21.53亿元，扣除发行费用后，实际募集资金净额为18.63亿元。百诚 医药最终募集资金净额比原计划多12.13亿元。百诚医药于2021年12月15日披露的招股说明书显示，公 司拟募集资金6.51亿元，全部用于杭州百诚医药科技股份有限公司总部及研发中心项目。 中国经济网北京8月18日讯百诚医药（301096）(301096.SZ)今日收报57.12元，跌幅10.62%。该股目前处 于破发状态。 百诚医药于2021年12月20日在深交所创业板上市，发行价格为79.60元/股。上市首日，百诚医药创下股 价高点120元，此后一路震荡下跌。 百诚医药公开发行股票2704.17万股，保荐机构(主承销商)为国金证券股份有限公司，保荐代表人为余 波、耿旭东。 据公司2024年年报，报告期内，公司实现营业收入8.02亿元，同比减少21.18%；归属于上市公司股东的 净利润-5274.28万元，同比减少119.39%；扣除非经常性损益后的净利润-7263.18万元，同比减少 128.07%；经营活动产生的现金流量净额-1.96亿元。 百诚医药发行费用总额为2.89亿元，其中国金证券股份有限公司获得 ...

企查查APP显示，近日，临海市浙生协同生命健康创业投资合伙企业（有限合伙）成立，出资额5亿 元，经营范围包含：创业投资（限投资未上市企业）；股权投资；以自有资金从事投资活动。企查查股 权穿透显示，该企业由百诚医药（301096）旗下杭州觅鹏企业管理合伙企业（有限合伙）等共同出资。 | 序号 | 合伙人名称 | 出资比例: | 认缴出资额; | | 认缴出资日期:首次持股日期:关联产品机构 | | | --- | --- | --- | --- | --- | --- | --- | | 1 | 浙江协同创新投资管理有限公司 | | | | 2025-08-14 | 浙江国际协 | | | 私募基金管理人 | | | | | 同创新 | | 2 | 临海市靖越金融投资集团有限公司 色 临海市调越金 6388 国有企业 | | | | 2025-08-14 | 临海国投集 网 | | | - REWERS PRESS CARS (ARRAK) | | | | 2025-08-14 百诚医药 | | | 3 | · 杭州百诚医药科技般份有限公司 11 | 95.00% | 11400万元 | 2050-12-31 ...